ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The French drugmaker Sanofi says it has decided not to divest Cepia, its contract manufacturing arm. The business produces active pharmaceutical ingredients at 16 Sanofi chemical and biotech sites. It also offers process development services. In the biotech field alone, the business counts more than 280 customers in 62 countries. The decision to keep Cepia is based on its financial improvement and promising prospects, Sanofi says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X